Scarica l'app Stockscreener
5.24
1.55%
0.08
Dopo l'orario di chiusura:
5.24
Precedente Chiudi:
$5.16
Aprire:
$5.33
Volume 24 ore:
104.60K
Relative Volume:
1.16
Capitalizzazione di mercato:
$87.55M
Reddito:
-
Utile/perdita netta:
$-12.36M
Rapporto P/E:
-3.9502
EPS:
-1.3265
Flusso di cassa netto:
$-11.39M
1 W Prestazione:
-11.04%
1M Prestazione:
-13.10%
6M Prestazione:
-17.87%
1 anno Prestazione:
-23.73%
Intervallo 1D:
$5.13
$5.6339
Intervallo di 1 settimana:
$5.07
$5.961
Portata 52W:
$4.75
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
Nome
Coya Therapeutics Inc
Settore
Industria
Telefono
650.739.3939
Indirizzo
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Confronta COYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.24 | 87.55M | 0 | -12.36M | -11.39M | -1.2511 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-04 | Iniziato | D. Boral Capital | Buy |
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Coya Therapeutics enrolls five in FTD study, eyes Phase 2 trial - Investing.com
Objective long/short (COYA) Report - Stock Traders Daily
Regulatory T-cells (Tregs) Therapies Market Key Players - openPR
Factors Influencing Global Regulatory T Cell Tregs Therapies - openPR
Exosome Therapeutics Market Applications in Neurological - openPR
Boral Capital initiates coverage on Coya Therapeutics with Buy rating By Investing.com - Investing.com Canada
Coya Therapeutics (NASDAQ:COYA) Now Covered by D. Boral Capital - MarketBeat
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference - StockTitan
Coya Therapeutics files to sell 1.38M shares of common stock for holders - MSN
Coya Therapeutics sets sights on neurodegenerative trials in 2025 - Investing.com India
Coya Therapeutics Advances $700M ALS Program, Sets Key 2025 Clinical Milestones | COYA Stock News - StockTitan
Trend Tracker for (COYA) - Stock Traders Daily
Insider Buying: CFO David Snyder Acquires Shares of Coya Therape - GuruFocus.com
Coya therapeutics CFO David Snyder buys $12,934 in stock - Investing.com
HC Wainwright Has Positive Forecast for COYA FY2024 Earnings - MarketBeat
Insider Buying: Coya Therapeutics Inc (COYA) Sees Purchase from Chief Medical Officer - GuruFocus.com
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Announces Earnings Results - MarketBeat
The Friday Biotech Perspective #32 - substack.com
Meet 5 of the fastest-growing scaleup companies in Houston - InnovationMap
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Coya Therapeutics Reports Q3 2024 Highlights and Progress - TipRanks
Coya Therapeutics board member resigns due to new job policy By Investing.com - Investing.com Canada
Coya Therapeutics Advances Pipeline for Neurodegenerative Diseases - TipRanks
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - The Bakersfield Californian
Coya Therapeutics board member resigns due to new job policy - Investing.com India
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics - pharmabiz.com
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress By Investing.com - Investing.com South Africa
Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Significant Increase in Short Interest - MarketBeat
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress - Investing.com
Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - StockTitan
Coya Therapeutics announces executive changes - Investing.com India
Coya Therapeutics Announces Leadership Change and New CEO - TipRanks
Coya Therapeutics announces executive changes By Investing.com - Investing.com UK
Coya Therapeutics On Developing A Combination Biologic - BioProcess Online
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off (NASDAQ:COYA) - Seeking Alpha
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results - Yahoo Finance
Coya Therapeutics reports promising Alzheimer's trial results By Investing.com - Investing.com South Africa
See the Impacts of Waco’s Walk to End Alzheimer’s - AOL
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Coya stock tumbles 23% on mixed results from Alzheimer's study - MSN
Coya stock tumbles 23% on mixed results from Alzheimer's study (NASDAQ:COYA) - Seeking Alpha
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth - Simply Wall St
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters
Coya Therapeutics reports promising Alzheimer's trial results - Investing.com
Coya Therapeutics Inc Azioni (COYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Coya Therapeutics Inc Azioni (COYA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):